Recent Publications by sanofi-synthelabo: |
Cannabis and the Course of Schizophrenia.
The discovery of two distinct cannabinoid receptors (CB1 and CB2) in the... | 3rd October, 2008
| Dr. Zullino receives or has received research support from the Swiss
| Am J Psychiatry. 2008 Oct;165(10):1357-1358.
DOI Direct Link |
Direct evidence for a furtive state in the degradation of carbasalatum calcicum.
The discovery of two distinct cannabinoid receptors (CB1 and CB2) in the... | 30th August, 2008
| Sanofi-SyntheLabo 371, Montpellier, France.
| Angew Chem Int Ed Engl. 2004 May 10;43(20):2694-7.
|
Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
Oxaliplatin (Eloxatin) is a third-generation platinum derivative with an... | 9th December, 2006
| Oncology Department, Sanofi-Synthelabo Recherche, F-34184 Montpellier
| Mol Cancer Ther. 2006 Sep;5(9):2149-57.
DOI Direct Link |
Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.
The aim of this study was to compare the relative bioavailability and the... | 9th December, 2006
| Sanofi-Synthelabo Research (Sanofi-Aventis group), Chilly-Mazarin, France.
| Fundam Clin Pharmacol. 2006 Aug;20(4):397-403.
DOI Direct Link |
Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.
Neuropilin 2 (NRP2) is a receptor for the vascular endothelial growth... | 13th September, 2006
| Angiogenesis and Thrombosis Department, Sanofi-Synthelabo Research, 31036
| Blood. 2006 Aug 15;108(4):1243-50. Epub 2006 Apr 18.
DOI Direct Link |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]
Patients with high blood pressure are often overweight or even obese.... | 5th August, 2006
| Institut fur Klinische Pharmakologie, Medizinische Fakultat, TU Dresden,
| MMW Fortschr Med. 2004 Aug 5;146 Suppl 2:45-50.
|
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Despite the well-documented effect of irbesartan, an angiotensin AT1... | 8th June, 2006
| Cardiovascular Research Department, Sanofi-Synthelabo Research, 1 Avenue
| Eur J Pharmacol. 2006 Mar 18;534(1-3):271-9. Epub 2006 Mar 6.
DOI Direct Link |
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
RATIONALE: Selective attention deficit, characterised by the inability to... | 11th April, 2006
| Sanofi-Synthelabo Recherche, CNS Research, 371 Rue du Pr Blayac, 34184
| Psychopharmacology (Berl). 2005 Aug;181(1):134-44. Epub 2005 Apr 14.
DOI Direct Link |
Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice.
In diabetic patients, impairment of wound healing is a serious problem... | 10th March, 2006
| Cardiovascular Thrombosis Department, Sanofi-Synthelabo Recherche, 195
| Eur J Pharmacol. 2006 Jan 4;529(1-3):172-8. Epub 2005 Dec 1.
DOI Direct Link |
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
We investigated the molecular events involved in the long-lasting... | 7th March, 2006
| Oncology Research Department, Sanofi-Synthelabo Recherche, Montpellier,
| FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11.
DOI Direct Link |
rdlA, a new gene encoding a rhodanese-like protein in Halanaerobium congolense and other thiosulfate-reducing anaerobes.
The recently described anaerobic moderately halophilic bacterium... | 4th February, 2006
| Sanofi-Synthelabo Recherche, 31676 Labege Cedex, France.
| Res Microbiol. 2005 Dec;156(10):1031-8. Epub 2005 Jul 13.
DOI Direct Link |
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Noncompetitive N-methyl-D-aspartate (NMDA) blockers induce... | 25th January, 2006
| CNS Department, Sanofi-Synthelabo Recherche, Bagneux, France.
| Neuropsychopharmacology. 2005 Nov;30(11):1963-85.
DOI Direct Link |
Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.
We investigated the effects of anandamide on peroxisome... | 13th September, 2005
| SANOFI-SYNTHELABO RECHERCHE, Oncology Department, 371 rue du Prof. Blayac,
| Eur J Pharmacol. 2005 Jul 11;517(3):174-81.
DOI Direct Link |
Two-sided tolerance intervals for balanced and unbalanced random effects models.
A procedure for constructing two-sided beta-content, gamma-confidence... | 12th July, 2005
| Preclinical and Research Statistics, Sanofi-Synthelabo Research Division,
| J Biopharm Stat. 2005;15(2):283-93.
|
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
Vasopressin (AVP) and corticotropin-releasing factor (CRF) are key... | 14th June, 2005
| Sanofi-Synthelabo Recherche, Exploratory Research Department, 195 route
| CNS Drug Rev. 2005 Spring;11(1):53-68.
|
